---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Humanistic burden and health-related quality of life. Topics: HDBOI study: EQ-5D-5L, SF-6D, and H-QoL-I scores by disease stage; Health state utility values: systematic literature review; Health state utility values: EHDN REGISTRY SF-6D analysis; Stage-specific utility values applied in a U.S. cost-effectiveness model; 17 further topics. 21 evidence topics quoted from 22 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### HDBOI study: EQ-5D-5L, SF-6D, and H-QoL-I scores by disease stage

> “A total of 2,094 PwHD were enrolled with completed eCRFs (100%) and PPIE-P forms (n = 482, 23%).”
> “The mean EQ-5D-5L (n = 336) utility score was 0.59 (SD, 0.27), with the highest mean utility scores [SD] in ES (0.72 [0.22]) followed by MS (0.62 [0.18]) and AS (0.37 [0.30]), p < 0.001.”
> “The mean SF-6D score (n = 482) was 0.57 (SD, 0.10), with mean values decreasing with advanced disease (ES, 0.61; MS, 0.56; AS, 0.50, p < 0.001).”
> “H-QoL-I mean scores (n = 482) also worsened with more advanced disease, from 0.58 for ES to 0.49 for MS and 0.37 for AS, p < 0.001.”
> “Overall proxy respondents reported on average worse outcomes than PwHD (self-reported) across all outcomes and disease stages suggesting a possible unawareness of deficits by PwHD.”

Source: [Rodriguez Santana et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9757103/)

<a id="topic-2.2.1.8.1-2"></a>

### Health state utility values: systematic literature review

> “Of 383 articles screened, 16 articles reported utility values estimated in 11 distinct studies.”
> “The EQ-5D index range was 0.89 - 0.72 for mild/prodromal HD and 0.71 - 0.37 for severe/late-stage disease.”
> “This study uncovered high variability in published utility estimates, indicating substantial uncertainty in existing data.”

Source: [Sawant et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11020898/)

<a id="topic-2.2.1.8.1-3"></a>

### Health state utility values: EHDN REGISTRY SF-6D analysis

> “11,328 questionnaires were completed by 5560 respondents with HD in 12 European countries.”
> “Women generally had lower HSUVs than men, and HSUVs were consistently lower than population norms for those with HD in the UK, and dropped with increasing disease severity.”
> “with TFC score, Behavioural score, and male gender significant predictors of SF-6D values (p < 0.001).”

Source: [Hawton et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6856291/)

<a id="topic-2.2.1.8.1-4"></a>

### Stage-specific utility values applied in a U.S. cost-effectiveness model

> “Health utilities for SoC were derived from the Hawton et al. study”
> “that used SF-6D preference-based measures to estimate stage-specific utilities for HD.”

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

| Health state | Utility, base case | Range |
| --- | --- | --- |
| Early | “0.73” | “0.7–0.9” |
| Middle | “0.63” | “0.5–0.7” |
| Late | “0.57” | “0.4–0.6” |

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

<a id="topic-2.2.1.8.1-5"></a>

### Norway cross-sectional study: EQ-5D-3L values by disease phase

> “Mean HRQoL values declined across disease phases for the 84 participants; early phase (n = 34): mean = 0.84 (SD = 0.13), middle phase (n = 19): mean = 0.74 (SD = 0.10) and advanced phase (n = 31): mean = 0.65 (SD = 0.5).”

Source: [van Walsem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9753307/)

<a id="topic-2.2.1.8.1-6"></a>

### Spain: H-QoL-I and EQ-5D-3L

> “Fifty-five patients and an equal number of caregivers participated.”
> “The usual activities and anxiety/depression were the most severely altered dimensions according to the EQ-5D-3L results.”
> “Increase of disease severity resulted in lower patient QoL.”

Source: [Dorey et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5065694/)

<a id="topic-2.2.1.8.1-7"></a>

### Chorea health states: time trade-off utility values in the general population

> “Mean ± SD TTO-derived utility values were 0.07 ± 0.52, 0.26 ± 0.50, 0.48 ± 0.47, and 0.64 ± 0.41 for severe, moderate/severe, moderate/mild, and mild chorea severity, respectively.”
> “Respondents were willing to give up 3.6, 5.2, 7.4, and 9.3 years during a 10-year life span to avoid living with mild, mild/moderate, moderate/severe, and severe chorea, respectively.”

Source: [Claassen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8990962/)

<a id="topic-2.2.1.8.1-8"></a>

### HDQLIFE: development of a disease-specific HRQoL measurement system

> “Existing item banks and new item pools were field tested in 536 individuals with prodromal, early-, or late-stage HD.”
> “HDQLIFE encompasses both validated Neuro-QoL/PROMIS measures, as well as five new scales in order to provide a comprehensive assessment of HRQOL in HD.”

Source: [Carlozzi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6108175/)

<a id="topic-2.2.1.8.1-9"></a>

### HDQLIFE physical function measures: reliability and validity

> “A total of 510 individuals with Huntington's disease completed 2 Quality of Life in Neurological Disorders (Lower Extremity Function and Upper Extremity Function) and 3 Huntington's Disease Health-Related Quality of Life (Chorea, Speech Difficulties, and Swallowing Difficulties) measures.”
> “Reliabilities for the new patient reported physical functioning measures were excellent (all Cronbach's α > .92).”

Source: [Carlozzi et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28556412/)

<a id="topic-2.2.1.8.1-10"></a>

### Chorea and HRQoL: U.S. online survey using HDQLIFE

> “A total of 115 participants (n = 35 caregivers; n = 80 individuals with HD) were included in this study.”
> “Among those experiencing chorea (n = 83, 74% of respondents), 66% indicated it was 'Very Important' to manage chorea; however, only 47% agreed that their current medication regimen helped manage their movements.”
> “significantly higher Anxiety (P = 0.0423) and stigma (P < 0.0001) scores were observed among respondents with high chorea than in those with low chorea.”

Source: [Thorley et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6132452/)

<a id="topic-2.2.1.8.1-11"></a>

### Determinants of HRQoL: functional capacity and depressive mood

> “Multiple regression analyses showed that functional capacity and depressive mood were significantly associated with HrQOL, in that greater impairments in HrQOL were associated with higher levels of depressive mood and lower functional capacity.”
> “Motor symptoms and cognitive function were not found to be as closely linked with HrQOL.”

Source: [Ho et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19097181/)

<a id="topic-2.2.1.8.1-12"></a>

### Psychiatric burden: suicidal ideation and sleep disturbance in the HDBOI study

> “PwHD reported current (13%, n = 272) or previous (28%, n = 575) suicidal ideation, which was more common with advanced HD (ES, 11%; MS, 14%; AS, 15%; p < 0.05).”
> “Of 482 questionnaire respondents, 91% (n = 437) reported difficulty sleeping, which was more common with AS HD (p < 0.05; [p = 0.000]).”

Source: [Rodríguez Santana et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11962051/)

<a id="topic-2.2.1.8.1-13"></a>

### Psychiatric burden: suicidal ideation measured with HDQLIFE Concern with Death and Dying items

> “We examined 496 participants with premanifest or manifest HD.”
> “Our sample had a significantly higher occurrence of suicidal ideation (19.76%) and suicidal plans (2.1%) than the general population (p < 0.0001).”

Source: [Wesson et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6108173/)

<a id="topic-2.2.1.8.1-14"></a>

### U.S. survey: individuals with HD and care partners compared with Parkinson's disease and the general population

> “IHD had greater comorbid anxiety (IHD = 51.2%, IPD = 28.8%, GP = 2.0%), and HD-CP had greater comorbid anxiety (HD-CP = 52.5%, PD-CP = 28.6%, GP-CP = 19.6%) and depression (HD-CP = 65.0%, PD-CP = 29.9%, GP-CP = 19.6%), relative to other cohorts (p < 0.05).”
> “Respective of their GP cohorts, IHD exhibited lower HRQoL (EQ-5D: 0.66 ± 0.21 vs. 0.81 ± 0.17) and greater depression (PHQ-9: 11.59 ± 7.20 vs. 5.85 ± 6.71), whereas HD-CP exhibited greater depression only (PHQ-9: 6.84 ± 6.38 vs. 4.15 ± 5.58) (p < 0.001).”

Source: [Exuzides et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8869871/)

<a id="topic-2.2.1.8.1-15"></a>

### Canada: HRQoL of individuals with HD and care partner strain

> “A total of 62 adult individuals with HD (or their proxies) and 48 care partners met defined eligibility criteria.”
> “For individuals with HD, the greatest HRQoL burden (i.e., lowest score) was for the SF-36v1 Role -Physical scale (46.8 [42.9]).”
> “Among care partners, 55.3% experienced high strain, as indicated by the CSI.”

Source: [Shaw et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9277690/)

<a id="topic-2.2.1.8.1-16"></a>

### Caregiver burden: prospective longitudinal study of patient and caregiver pairs

> “105 caregiver/patient pairs were included in the analysis.”
> “Of the two clusters of patients with advanced disease, cluster A was characterized by high levels of irritability and obsessive-compulsive behaviors, with high and increasing burden (N = 30; 29%), cluster B, the more apathetic group, with low and decreasing burden (N = 22; 21%).”

Source: [Youssov et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36084356/)

<a id="topic-2.2.1.8.1-17"></a>

### Caregiver burden: determinants in a U.S. clinic sample

> “Total functional capacity and being sole caregiver were significantly associated with higher caregiver burden via MCSI.”

Source: [Yu et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30594932/)

<a id="topic-2.2.1.8.1-18"></a>

### Caregiver burden: South Korea prospective cohort

> “Sixty-five patients with HD and 45 caregivers were enrolled in this cohort study.”
> “A higher caregiver burden was associated with a more severe Shoulson-Fahn stage (p = 0.038) of the patients.”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10846961/)

<a id="topic-2.2.1.8.1-19"></a>

### Caregiver burden: systematic review

> “Twelve studies were included in the review involving 569 caregivers of patients with HD.”
> “Neuropsychiatric symptoms and the hereditary nature of the disease have been identified as important correlates of caregiver strain.”

Source: [Poprelka et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40938830/)

<a id="topic-2.2.1.8.1-20"></a>

### Patient and caregiver experience: ICER stakeholder input

> “Caregiver impact increases as the disease progresses and individuals become more dependent on others, with 24/7 care eventually needed, particularly during the last five years of life.”
> “Motor symptoms are also a prominent feature of the disease and affect individuals’ ability to walk, talk, eat, and sleep.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/08/Huntingtons-Disease_Draft-Scope_For-Publication_082026_For-Publication.pdf)

<a id="topic-2.2.1.8.1-21"></a>

### Multigenerational burden: qualitative study across six European countries

> “Cognitive and psychiatric symptoms were particularly burdensome, driving declines in quality of life (QoL) and emotional well-being.”
> “Caregivers reported extensive physical, financial, and psychological strain, with many assuming care responsibilities from a young age or eventually caring for multiple relatives.”

Source: [Smith et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13522420/)

Additional sources: [Hergert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33723593/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
